Regeneron Pharmaceuticals (NASDAQ:REGN) Sets New 12-Month High Following Analyst Upgrade

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares hit a new 52-week high during mid-day trading on Monday after JPMorgan Chase & Co. raised their price target on the stock from $1,050.00 to $1,150.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Regeneron Pharmaceuticals traded as high as $1,044.77 and last traded at $1,042.89, with a volume of 96066 shares changing hands. The stock had previously closed at $1,036.52.

Several other equities research analysts have also recently commented on REGN. Evercore ISI began coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 price target for the company. Bank of America upped their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research report on Friday, April 12th. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 30th. Sanford C. Bernstein began coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price objective for the company. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $925.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, May 3rd. One analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $998.09.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CEO Leonard S. Schleifer sold 25,000 shares of the business’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the sale, the chief executive officer now owns 408,200 shares of the company’s stock, valued at $399,729,850. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 25,000 shares of the business’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the sale, the chief executive officer now directly owns 408,200 shares of the company’s stock, valued at approximately $399,729,850. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Leonard S. Schleifer sold 787 shares of the stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $1,015.02, for a total transaction of $798,820.74. Following the transaction, the chief executive officer now owns 64,198 shares of the company’s stock, valued at $65,162,253.96. The disclosure for this sale can be found here. Insiders sold 61,215 shares of company stock valued at $60,414,782 in the last ninety days. 7.48% of the stock is currently owned by corporate insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in REGN. West Paces Advisors Inc. grew its holdings in Regeneron Pharmaceuticals by 575.0% during the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 23 shares during the period. Crewe Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $28,000. Fortitude Family Office LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $31,000. MCF Advisors LLC raised its stake in Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 12 shares during the period. Finally, Criterion Capital Advisors LLC acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $37,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

The stock has a market capitalization of $115.19 billion, a P/E ratio of 30.88, a PEG ratio of 2.14 and a beta of 0.13. The stock’s 50-day simple moving average is $958.43 and its 200 day simple moving average is $938.09. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing the consensus estimate of $8.46 by ($0.49). The company had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current fiscal year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.